XENE GoodMoat Verdict
Full signal breakdown coming soon. Use the X-Ray tool for a detailed analysis.
Xenon Pharmaceuticals Inc
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications.
Current Price
$54.12
-1.02%Profile
Valuation (TTM)
Market Cap$4.50B
P/E-11.75
EV—
P/B7.74
Shares Out83.19M
P/Sales—
Revenue$0.00
EV/EBITDA—
Xenon Pharmaceuticals Inc (XENE) Quality Analysis
XENE Profitability
Profitability trend analysis coming soon
XENE Growth
Growth trend analysis coming soon
XENE Financial Health
Financial health indicators coming soon
XENE Quality & Fundamental Analysis
Xenon Pharmaceuticals Inc (XENE) is a Healthcare company in the Biotechnology industry, listed on NASDAQ. This quality analysis page evaluates Xenon Pharmaceuticals Inc's financial health using the Piotroski F-Score methodology, profitability ratios, growth trajectory, and balance sheet strength.
Xenon Pharmaceuticals Inc has a Piotroski F-Score of N/A out of 9, measuring profitability, leverage, and operating efficiency. and a return on equity (ROE) of -65.86%. Return on assets (ROA) stands at -60.52%.
The debt-to-equity ratio is 0.01, with a current ratio of 13.42. Operating margin is -4974.27%.
GoodMoat's quality analysis uses AI-powered insights to evaluate whether Xenon Pharmaceuticals Inc is a fundamentally sound investment. The GoodMoat Verdict synthesizes profitability, growth, and financial health scores into a clear investment quality rating. Use these metrics alongside valuation tools like the DCF calculator and fair value models to make informed investment decisions.